MeiraGTx Holdings plc
IPONext-Gen Genetic Medicine - MeiraGTx
Public · New York, United States · Founded 2015 · $220.0M raised
- Headquarters
- New York, New York
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- meiragtx.com
- Total Funding
- $220.0M
- Last Round
- $100.0M Corporate RoundApr 2026
- Rounds
- 3
- Type
- Public
About
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with four late-stage clinical programs targeting the eye, Parkinson's disease, and xerostomia. The company uses innovative capsid, promoter, and translational control technologies to develop potent viral vectors, supported by end-to-end in-house GMP manufacturing. MeiraGTx has also developed a proprietary riboswitch platform enabling oral small molecule control of in vivo gene expression for metabolic and oncology applications.
Summary
MeiraGTx Holdings plc is a Biotech company based in New York, United States, founded in 2015. It has raised $220.0M in total across 3 rounds, most recently a $100.0M Corporate Round round in Apr 2026. Investors include Sanofi Ventures and UCL Technology Fund.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2026
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...